Unraveling the molecular mechanisms behind the metabolic basis of sporadic alzheimer's disease

Journal of Alzheimer's Disease

Volumn 17, Issue 2, 2009, Pages 267-276

  Erol, Adnan ^a,b  

^a Department of Internal Medicine   (Turkey)

^b NAMIK KEMAL UNIVERSITY   (Turkey)

Author keywords

Alzheimer's disease; FOXO; GSK3; Insulin resistance; JNK; P53

Indexed keywords

AMYLOID BETA PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN SYNTHASE KINASE 3; INSULIN; PROTEIN KINASE B; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN METABOLISM; HYPERINSULINEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; METABOLIC DISORDER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

EID: 67849110363     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1047     Document Type: Review

References (69)

1. Erol A (2008) An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. JAlzheimers Dis 13, 241-253.
2. Banks WA, Jaspan JB, Kastin AJ (1997) Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin. Peptides 18, 1577-1584.
3. Selkoe DJ (2002) Alzheimer's disease a synaptic failure. Science 298, 789-791.
4. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and taupathies. Curr Alzheimer Res 2, 3-18.
5. Babu JR, Seibenhener ML, Peng J, Strom A-L, Kemppainen R, Cox N, Zhu H, Wooten MC, Diaz-Meco MT,Moscat J, wooten MW (2008) Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. JNeurochem 106, 107-120.
6. Pearson AG, Byrne UTE, MacGibbon GA, Faull RLM, Dra- gunow M (2006) Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains. Neurosci Lett 398, 246-250.
7. van der Heide LP, Ramakers GMJ, Smidt MP (2006) Insulin signaling in the central nervous system: Learning to survive. Prog Neurobiology 79, 205-221.
8. Whiteman EL, Cho H, Birnbaum MJ (2002) Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 13, 444-451.
9. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N (2001) Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15, 1406-1418.
10. Jope RS, Yuskatis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32, 577-595.
11. Grimes CA, Jope RS (2001) The multi-faceted roles of glycogen synthase kinase-3/3 in cellular signaling. Prog Neurobiol 65, 391-426.
12. Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116, 1175-1186.
13. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3β regulate production of Alzheimer's disease amyloid-/ peptides. Nature 423, 435-439.
14. Cho JH, Johnson GVW (2004) Primed phosphorylation of tau at Thr 231 by glycogen synthase kinase 3/3 (GSK3/3) plays a critical role in regulating tau's ability to bind and stabilize microtubules. JNeurochem 88, 349-358.
15. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS (2003) Glycogen synthase-3/J (GSK3//) binds to and promotes the actions ofp53. JBiol Chem 278, 48872-48879.
16. Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410-7425.
17. Van der Heide LP, Hoekman MF, Smidt MP (2004) The ins and outs ofFoxO shuttling mechanisms ofFoxO translocation and transcriptional regulation. Biochem J380, 297-309.
18. Vogt PK, Jiang H, Aoki M (2005) Triple layer control. Cell Cycle 4, 908-913.
19. Jacobs FMJ, van der Heide LP, Wijchers PJEC, Burbach JP, Hoekman MF, Smidt MP (2003) FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J Biol Chem 278, 35959-35967.
20. 184, independent of nucleo-cytoplasmic shuttling. Biochem J391, 623-629.
21. Acilli D, Arden KC (2004) FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421-426.
22. Huang H, Tindall DJ (2007) Dynamic FoxO transcription factors. JCell Sci 120, 2479-2487.
23. Kops KJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM (2002) Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419, 316-321.
24. Essers MAG, Weijzen S, de Vries-Smits AMM, Saarloos I, de Rutter ND, Bos JL, Burgering BM (2004) FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J23, 4802-4812.
25. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, DiSte- fano PS, Chiang LW, Greenberg ME (2002) DNA repair path-way stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296,530-534.
26. Shaw J, Kirshenbaum LA (2006) Prime time for JNK- mediated Akt reactivation in hypoxia-reoxygenation. Circ Res 98, 7-9.
27. Webster KA (2004) Aktion in nucleus. Circ Res 94, 856-859.
28. Tran H, Brunet A, Griffith EC, Greenberg ME (2003) The many forks in FOXO's road. Sci STKE172, RES.
29. Gilley J, Ceffer PJ, Ham J (2003) FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162, 613-622.
30. Baines CP, Molkentin JD (2003) STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 35, 1385-1394.
31. Kogel D, Schomburg R, Copanaki E, Prehn JH (2005) Regulation of gene expression by the amyloid precursor protein: inhibition of the JNK/c-jun pathway. Cell Death Differ 12, 1-9.
32. Ventura JJ, Hubner A, Zhang C, Flavell RA, Shokat KM, Davis RJ (2006) Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell 21, 701-710.
33. Bogoyevitch MA, Kobe B Uses for JNK. (2006) The many and varied substrates of the c-Jun N-terminal kinases. Microbiol Molecul Biol Rev 70, 1061-1095.
34. Shen C, Chen Y, Liu H, Zhang K, Zhang T, Lin A, Jing N (2008) Hydrogen peroxide promotes Abeta production through JNK-dependent activation ofgamma-secretase. JBiol Chem 283, 7721-17730.
35. Yoshida H, Hastie CJ, McLauchlan H, Cohen P, Goedert M (2004) Phosphorylation of microtubule-associated protein tau by isoforms of c-jun N-terminal kinase (JNK). J Neurochem 90, 352-358.
36. Sahara N, Murayama M, Lee B, Park JM, Lagalwar S, Binder LI, Takashima A (2008)Active c-jun N-terminal kinase induces caspase cleavage oftau and additional phosphorylation by GSK-3beta is required fortau aggregation. Eur J Neurosci 27, 2897-2906.
37. Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN, Ronai Z (1998) JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 12, 2658-2663.
38. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S, Fried VA, Minamoto T, Alarcon-Vargas D, Pincus MR, Gaarde WA, Hulbrook NJ, Shiloh Y, Ronai Z (2001) Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Moll Cell Biol 21, 2743-2754.
39. Zhu X, Raina AK, Perry G, Smith MA (2004) Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 3, 219-226.
40. Smith MA, Rothcamp CA, Nunomura A, Raina AK, Perry G (2000) Oxidative stress in Alzheimer's disease. Biochim BiophysActa 1502, 139-144.
41. Misonou H, Morishima-Kawashima M, Ihara Y (2000) Ox- idative stress induces intracellular accumulation of amyloid β-protein (Aβ) in human neuroblastoma cells. Biochemistry 39, 6951-6359.
42. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639.
43. Castellani RJ, Nunomura A, Lee HG, Perry G, Smith MA (2008) Phosphorylated tau: toxic, protective, or none of the above. Alzheimers Dis 14, 377-383.
44. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA (2001) Activation and redistribution of c-Jun N- terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. Neurochem 76, 435-441.
45. Cole AR, Astell A, Green C, Sutherland C (2007) Molecular connexions between dementia and diabetes. Neurosci Biobe- havRev 31, 1046-1063.
46. Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Berbard G (2005) Ineffective phagocytosis ofamyloid-beta by macrophages ofAlzheimer's disease patients. Alzheimers Dis 7, 221-232.
47. Senokuchi T, Liang CP, Seimon TA, Han S, Matsumoto M, Banks As, Paik JH, DePinho RA, Accili D, Tabas I, Tall AR (2008) Forkhead transcription factors (FoxOs) promote apoptosis ofinsulin resistant macrophages during cholesterol- induced endoplasmic reticulum stress. Diabetes 57, 2967-2976.
48. Fiala M, Cribbs DH, Rosenthal M, Bernard G (2007) Phago cytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. Alzheimers Dis 11, 457-463.
49. Chong ZZ, Li F, Maiese K (2005) Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol 20, 299-315.
50. Dervish AMS, Brunet A (2008) FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol 20, 126-136.
51. Sunayama J, Tsuruta F, Masuyama N. Gotoh Y (2005) JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. Cell Biol 170, 295-304.
52. Magrane J, Rosen KM, Smith RC, Walsh K, Gouras GK, Ouerfurth HW (2005) Intraneuronal beta-amyloid expression down regulates the Akt survival pathway and blunts the stress response. Neurosci 25, 10960-10969.
53. You H, Mak TW (2005) Crosstalk between p53 and FOXO transcription factors. Cell Cycle 4, 37-38.
54. Vousden KH (2006) Outcomes of p53 activation - spoilt for choice. Cell Sci 119, 5015-5020.
55. Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4, 147-152.
56. Boudewijn M, Burgering T, Medema RH (2003) Decisions on life and death: FOXO forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 73, 689-701.
57. Christensen DD (2007) Alzheimer's disease: progress in the development ofanti-amyloid disease-modifying therapies. CNSSpectr 12, 113-116.
58. Medina M, Castro A (2008) Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel 11, 533-543.
59. Patel S, Woodget J (2008) Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 14, 351-353.
60. Hong M, Chen DC, Klein PS, Lee VM (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase- 3. JBiol Chem 272, 25326-25332.
61. Hongisto V, Smeds N, Brecht S, Herdegen T, Courtney MJ, Coffey ET(2003) Lithium blocks the c-Junstress response and promotes neurons via its action on glycogen synthase kinase 3. Mol Cell Biol 23, 6207-6036.
62. Mao Z, Liu L, Zhang R, Li X (2007) Lithium reduces FoxO3a transcriptional activity by decreasing its intracellular content. Biol Psychiatry 62, 1423-1430.
63. Erol A (2007) Insulin resistance is an evolutionarily conserved physiological mechanism at the cellular level for protection against increased oxidative stress. Bioessays 29, 811-818.
64. Chen MJ, Russo-Neustadt AA (2005) Exercise activates the phosphatidylinositol 3-kinase pathway. Mol Brain Res 135, 181-190.
65. Um HS, Kang EB, Leem YH, Cho IH, Yang CH, Chae KR, Hwang DY, Cho JY (2008) Exercise training acts as a therapeutic strategy for reduction of pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int J Mol Med 22, 529-539.
66. Toldy A, Stadler K, Sasvari M. Jakus J, Jung KJ, Chung HY, Berkes I, Nyakas C, Radak Z (2005) The effect of exercise s of Alzheimer's Disease and nettle supplementation on oxidative stress markers in the rat brain. Brain Res Bull 65, 487-493.
67. Craft S (2005) Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid and inflammation. Neurobiol Aging 26Suppl, 65-69.
68. Erol A (2007) JNK/FOXO may be key mechanistic pathway for the hormetic anti-aging. Med Hypotheses 68, 923-924.
69. Larson EB (2008) Physical activity for older adults at risk for Alzheimer disease. JAMA 300, 1077-1079.